Vera Therapeutics, Inc. (NASDAQ:VERA) is one of the best small cap stocks with the highest upside. BofA initiated coverage of Vera Therapeutics, Inc. (NASDAQ:VERA) with a Buy rating and a $48 price target on October 16.
The firm told investors that it sees potential upside in the company’s shares because of its lead drug, atacicept, a novel biologic investigational therapeutic launching into a multibillion-dollar market.
The firm also stated that its $3 billion nominal peak sales estimation for 2037 shows atacicept’s potential as a favorable treatment option in several autoimmune disorders, pending future clinical data validation.
Vera Therapeutics, Inc. (NASDAQ:VERA) is a clinical-stage biotechnical company that develops and commercializes transformative treatments for immunological diseases.
While we acknowledge the potential of VERA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.